Global Circulating Tumor Cells (CTC) Market - Segmented by Technology, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)
The circulating tumor cells (CTC) market is expected to register a growth rate of nearly 9.0% during the forecast period, 2018-2023. The CTC refers to the tumor cells which are circulating inside the body through blood circulation system and lymphatic system. Its market is expected to grow steadily due to the high prevalence of cancer and increasing demand for preventive medicine with the need for companion diagnostics. As per the study scope of geographical regions, North America is estimated to witness high growth rate with high share in this market due to the well-established healthcare infrastructure with high adoption of advanced diagnostic technologies and rising demand of research projects for cancers.
Growing Prevalence of Cancer
The growing prevalence of cancer patients has a direct impact on increased demand for CTC market. Cancer is one of the most lethal diseases worldwide which is primarily related to growth in mortality per year. Several types of cancers occur due to genetic disorders, lifestyle changes, high consumption of alcohol and smoking, all contributing to the demand for diagnosis of CTC in the patients with cancers. The CTCs have been identified in several cancer types and act as promising circulating biomarkers. In one of the published articles of 2016 in Bioscience Reports, the study shiwed different physical and molecular properties of CTCs which could be correlated with different types of cancers, its staging and treatment response. Thus, increasing prevalence of different types of cancers directly benefits the growth of CTC market.
Other driving factors for this market include the development of cluster chip technology for capturing clusters of CTCs, advancements in biomedical imaging and bioengineering technology and increasing demand for preventive medicine and companion diagnostics.
Technical Difficulties in Detection and Characterization of CTCs
The CTCs diagnosis takes place in many clinical trials however their detection and characterization is highly difficult because of their extremely rare presence (one cell per 10 to power 9 hematologic cells) which further requires stringent and effective isolation and enrichment from blood, as per the 2016 publication in Bioscience Reports. The inter-tumor cancer cell genetic heterogeneity including its metastatic potential and cell fusion, limits CTCs identification. Further, this raises the cost of detection process accompanied by lack of specific biomarkers to detect CTCs. Thus, the technical limitations for the detection of CTCs, impedes the growth of this market.
Other factors limiting the growth of this market are lack of awareness and unwillingness for the adoption of advanced CTC technologies.
Asia Pacific to Witness the Fastest Growth Rate
The market of CTCs for Asia-Pacific region is expected to increase with the fastest growth rate during the estimation period, 2018 to 2023. The healthy CAGR is expected due to rising healthcare expenditure for in countries such as India, China and Japan. One of the articles published in the Chinese Journal of cancer Research reported that during the period of 2011 to 2015, cancer inpatients payments increased by nearly 84% to reach to about 180 billion RMB. This reflects an increasing awareness in public for early diagnosis and treatment of cancer. Further, the increasing government initiatives for cancer awareness, rise in research and development investments helps in the growth of this market, followed by the diversified patient pool of cancer and genetic disorders.
Key Developments in the Market
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook